Pharmacogenomics: a reality or still a promise?

Gerold Bepler

Open access · greenAbstract read

In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

2.0field-weighted citation impact, top 13% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2010
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gerold BeplerH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. beplerg@moffitt.usf.edu

Moffitt Cancer Center · US

Funding

RRM1/PTEN Axis in Non-Small Cell Lung CancerR01CA102726 · NCI · H. LEE MOFFITT CANCER CTR &RES INST · PI BEPLER, GEROLD · 2003 to 2007

$2.6M

Enhancing neoadjuvant chemotherpay responses with targeted T cellsR01CA140314 · NCI · WAYNE STATE UNIVERSITY · PI BEPLER, GEROLD · 2010 to 2015

$2.5M

Pharmacogenomics of Neoadjuvant Gemcitabine-Pemetrexed *R21CA110487 · NCI · H. LEE MOFFITT CANCER CTR &RES INST · PI BEPLER, GEROLD · 2005 to 2006

$581k

NCI NIH HHS R01 CA 102726NCI NIH HHS R01 CA102726NCI NIH HHS R01 CA140314NCI NIH HHS R21 CA 106616NCI NIH HHS R21 CA110487

6 · The paper itself

Abstract

Although notable progress has been made in the treatment of non-small-cell lung cancer (NSCLC) in recent years, this disease is still associated with a poor prognosis for most patients. Modern techniques have facilitated the identification of specific genetic factors that may play a role in disease progression and patient response to therapy, prompting research efforts to identify the clinical predictors of outcome for NSCLC. Recent evidence suggests that the application of a pharmacogenomic approach has the potential to greatly improve survival in certain subpopulations of patients with NSCLC, which could profoundly influence the decision-making process used in evolving treatment strategies for this malignancy.

Indexed as

PharmacogeneticsAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDNA-Binding ProteinsDNA, NeoplasmEndonucleasesGene Expression Regulation, NeoplasticHumansLung NeoplasmsRibonucleoside Diphosphate ReductaseTreatment OutcomeTumor Suppressor ProteinsAntineoplastic AgentsDNA-Binding ProteinsDNA, NeoplasmEndonucleasesERCC1 protein, humanRibonucleoside Diphosphate ReductaseRRM1 protein, humanTumor Suppressor Proteins

Identifiers

PMID17064812

DOI10.1016/j.lungcan.2006.09.014

PMCPMC1759823

OpenAlexW2054989759

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.